Amylyx Pharmaceuticals’ AMX0035 misses primary and secondary endpoints in ALS study
Cambridge, Massachusetts-based Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX), a key player in the pharmaceutical industry, announced today the top-line results of the PHOENIX study, a critical ... Read More